Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $330.5 million.

  • Cytokinetics' Cash from Financing Activities rose 9548.64% to $330.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.1 million, marking a year-over-year decrease of 62.07%. This contributed to the annual value of $930.6 million for FY2024, which is 320.49% up from last year.
  • Per Cytokinetics' latest filing, its Cash from Financing Activities stood at $330.5 million for Q3 2025, which was up 320.80% from $78.5 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Cash from Financing Activities registered a high of $821.0 million during Q2 2024, and its lowest value of -$7.2 million during Q1 2023.
  • For the 3-year period, Cytokinetics' Cash from Financing Activities averaged around $142.3 million, with its median value being $54.2 million (2023).
  • Per our database at Business Quant, Cytokinetics' Cash from Financing Activities tumbled by 32,590.91% in 2021 and then surged by 14,895.63% in 2024.
  • Cytokinetics' Cash from Financing Activities (Quarterly) stood at $19.5 million in 2021, then soared by 53.21% to $29.9 million in 2022, then surged by 464.83% to $168.8 million in 2023, then slumped by 98.59% to $2.4 million in 2024, then spiked by 9,548.64% to $330.5 million in 2025.
  • Its Cash from Financing Activities stands at $330.5 million for Q3 2025, versus $78.5 million for Q2 2025 and $4.8 million for Q1 2025.